Literature DB >> 16127069

Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Patricia A Bradford1, Peter J Petersen, Mairead Young, C Hal Jones, Mark Tischler, John O'Connell.   

Abstract

Tigecycline is a broad-spectrum glycylcycline antibiotic with activity against not only susceptible gram-positive and gram-negative pathogens but also strains that are resistant to many other antibiotics. In the process of determining quality control (QC) limits for the American Type Culture Collection reference strains for tigecycline, a number of inconsistencies in MICs were encountered which appeared to be related to the age of the Mueller-Hinton broth (MHB) medium used in the MIC testing. The objective of this study was to determine the cause of the discrepant MIC results between fresh and aged MHB. The MICs of tigecycline were determined in MHB that was either prepared fresh (<12 h old), prepared and stored at 4 degrees C, stored at room temperature, stored anaerobically, or supplemented with the biocatalytic oxygen-reducing reagent Oxyrase. When tested in fresh media, tigecycline was 2 to 3 dilutions more active against the CLSI-recommended QC strains compared to aged media (MICs of 0.03 to 0.25 and 0.12 to 0.5 mug/ml, respectively). Media aged under anaerobic conditions prior to testing or supplemented with Oxyrase resulted in MICs similar to those obtained in fresh medium (MICs of 0.03 to 0.12 and 0.03 to 0.25 mug/ml, respectively). Time-kill kinetics demonstrated a >3 log(10) difference in viable growth when tigecycline was tested in fresh or Oxyrase-supplemented MHB compared to aged MHB. High-pressure liquid chromatography analysis revealed the accumulation of an early peak (oxidative by-product of tigecycline) to be 3.5% in fresh media and 25.1% in aged media after 24 h and that addition of Oxyrase prevented the accumulation of this oxidized by-product. These results suggested that the activity of tigecycline was affected by the amount of dissolved oxygen in the media. The use of fresh MHB or supplementation with Oxyrase resulted in a more standardized test method for performing MIC tests with tigecycline.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127069      PMCID: PMC1195415          DOI: 10.1128/AAC.49.9.3903-3909.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

2.  In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Int J Antimicrob Agents       Date:  2000-09       Impact factor: 5.283

3.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

4.  Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus.

Authors:  Donald E Low; Barry N Kreiswirth; Karl Weiss; Barbara M Willey
Journal:  Int J Antimicrob Agents       Date:  2002-09       Impact factor: 5.283

5.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline.

Authors:  C Edlund; C E Nord
Journal:  Clin Microbiol Infect       Date:  2000-03       Impact factor: 8.067

7.  Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

Authors:  P E Sum; P Petersen
Journal:  Bioorg Med Chem Lett       Date:  1999-05-17       Impact factor: 2.823

8.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  In vitro activities of tigecycline against the Bacteroides fragilis group.

Authors:  N V Jacobus; L A McDermott; R Ruthazer; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  32 in total

1.  Effect of manganese in test media on in vitro susceptibility of Enterobacteriaceae and Acinetobacter baumannii to tigecycline.

Authors:  J Veenemans; J W Mouton; J A J W Kluytmans; R Donnely; C Verhulst; P H J van Keulen
Journal:  J Clin Microbiol       Date:  2012-06-20       Impact factor: 5.948

2.  High-Throughput Intracellular Antimicrobial Susceptibility Testing of Legionella pneumophila.

Authors:  Lucius Chiaraviglio; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

Review 3.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.

Authors:  Peter J Petersen; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Postantibiotic effect of tigecycline against 14 gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

7.  High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest.

Authors:  Carlos Fernández-Mazarrasa; Olav Mazarrasa; Jorge Calvo; Asunción del Arco; Luis Martínez-Martínez
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

8.  IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae.

Authors:  Lindsey E Nielsen; Erik C Snesrud; Fatma Onmus-Leone; Yoon I Kwak; Ricardo Avilés; Eric D Steele; Deena E Sutter; Paige E Waterman; Emil P Lesho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.

Authors:  Catherine L Clark; Klaudia Kosowska-Shick; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.